New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 27, 2014
06:01 EDTUTHRUnited Therapeutics announces additional $500M share repurchase program
United Therapeutics announced that its board authorized the repurchase of up to an additional $500M of the company's common stock. This program will become effective on August 1, and will remain open for up to one year. The company also announced that it had recently completed its previously-announced repurchase program by purchasing a total of approximately 4.6 million shares of its common stock.
News For UTHR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 17, 2014
06:11 EDTUTHRUnited Therapeutics changes CEO compensation structure
Subscribe for More Information
06:09 EDTUTHRUnited Therapeutics names Roger Jeffs co-CEO and David Zaccardelli as COO
United Therapeutics announced two senior executive promotions: Roger Jeffs has been promoted to President and Co-CEO and David Zaccardelli to Executive VP and COO. CEO Rothblatt's title will change to Chairman and Co-CEO. As Chairman of the Board and Co-CEO, Rothblatt will continue to serve as the principal executive officer of the company. These title changes will become effective January 1, 2015. Jeffs joined United Therapeutics in 1998 and currently serves as the company's President and COO since 2001. Zaccardelli currently serves as Chief Manufacturing Officer and EVP, Pharmaceutical Development, a position he has held since 2008.
December 11, 2014
10:13 EDTUTHROn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: ARIAD (ARIA) downgraded at Credit Suisse... AbbVie (ABBV) downgraded to Equal Weight from Overweight at Morgan Stanley... Aimco (AIV) downgraded to Hold from Buy at KeyBanc... Anglo American (AAUKY) downgraded to Underperform from Neutral at Exane BNP Paribas... Approach Resources (AREX) downgraded at Sterne Agee... CommVault (CVLT) downgraded to Neutral from Outperform at Macquarie... Fifth Street Senior (FSFR) downgraded to Perform from Outperform at Oppenheimer... Harmonic (HLIT) downgraded to Neutral from Buy at Sidoti... Macerich (MAC) downgraded to Hold from Buy at Deutsche Bank... Newell Rubbermaid (NWL) downgraded to Outperform from Strong Buy at Raymond James... Olin Corp. (OLN) downgraded at Longbow... Penn West (PWE) downgraded to Underperform from Neutral at BofA/Merrill... Prudential plc (PUK) downgraded to Neutral from Buy at Nomura... Semiconductor Manufacturing (SMI) downgraded to Hold from Buy at Jefferies... Suncor (SU) downgraded to Neutral from Buy at BofA/Merrill... Talisman Energy (TLM) downgraded to Underperform from Neutral at BofA/Merrill... Thompson Creek (TC) downgraded to Hold from Buy at Deutsche Bank... Toll Brothers (TOL) downgraded to Underperform from Sector Perform at RBC Capital... Travelers (TRV) downgraded to Neutral from Buy at UBS... United Therapeutics (UTHR) downgraded at Credit Suisse... Vera Bradley (VRA) downgraded to Underperform from Neutral at Sterne Agee.
08:21 EDTUTHRUnited Therapeutics downgraded at Credit Suisse
As previously reported, Credit Suisse downgraded United Therapeutics to Underperform from Neutral. The analyst has increased concerns regarding long-term competitive threats for the PAH franchise based on Remodulin's patent expiration in October 2017 and the launch of ATLN's Selexipag in 2016. Price target raised to $120 from $100.
06:35 EDTUTHRUnited Therapeutics downgraded to Underperform from Neutral at Credit Suisse

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use